[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-438696-105":59,"doc-detail-438696-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","correction-correction-surgery-for-retroperitoneal-soft-tissue-sarcoma-is-safe-following-multimodal-treatment-with-regional-hyperthermia","Correction - Correction - Surgery for Retroperitoneal Soft Tissue Sarcoma is Safe Following Multimodal Treatment with Regional Hyperthermia","","Correction notice for the article “Surgery for Retroperitoneal Soft Tissue Sarcoma is Safe Following Multimodal Treatment with Regional Hyperthermia.” Tables 3 and 4 initially omitted modeled estimates of the Comprehensive Complication Index (CCI) by treatment group that were included as fixed effects in the zero-inflated beta models. The revised tables now report modeled probabilities of any postoperative complication (CCI > 0) and expected CCI severity (0 \u003C CCI \u003C 100) by treatment group. Updates also include Supplemental Tables 3-4 and Tables 7-8 for primary and recurrent tumor models, without changing study results or conclusions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/correction-correction-surgery-for-retroperitoneal-soft-tissue-sarcoma-is-safe-following-multimodal-treatment-with-regional-hyperthermia/438696/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/correction-correction-surgery-for-retroperitoneal-soft-tissue-sarcoma-is-safe-following-multimodal-treatment-with-regional-hyperthermia/438696.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was corrected in the published article?","Question",{"text":112,"@type":113},"Tables 3 and 4 were initially missing the modeled Comprehensive Complication Index (CCI) estimates by treatment group.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What do the corrected Table 3 and Table 4 report?",{"text":117,"@type":113},"Table 3 reports modeled probabilities of postoperative complications (CCI > 0), while Table 4 includes expected CCI severity values (0 \u003C CCI \u003C 100) by treatment group.",{"name":119,"@type":110,"acceptedAnswer":120},"Do the corrections change the study’s conclusions?",{"text":121,"@type":113},"No. The correction notice states that the corrected tables complete the primary outcome presentation and do not alter the study’s results or conclusions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},438696,1790746632,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Ann Surg Oncol (2026) 33:1725–1727  \n[https://doi.org/10.1245/s10434-025-18730-7](https://doi.org/10.1245/s10434-025-18730-7)  \nCORRECTION  \nCorrection: Surgery for Retroperitoneal Soft Tissue Sarcoma is Safe Following Multimodal Treatment with Regional  \nHyperthermia  \nMathilda Knoblauch, MD1, Cathy Werdel1, Yanik Arlt, MD1, Lars H. Lindner, MD2, Dorit Di Gioia, MD2, Anton Burkhard‑Meier, MD2, Luc Berclaz, MD2, Nina‑Sophie Schmidt‑Hegemann, MD3, Paul Schmidt4, Jens Werner, MD1, and  \nMarkus Albertsmeier, MD1  \n1Department of General, Visceral and Transplantation Surgery, Ludwig Maximilians Universität (LMU) Munich, LMU Hospital, Munich, Germany; 2Department of Medical Oncology, Ludwig Maximilians Universität (LMU) Munich, LMU Hospital, Munich, Germany; 3Department of Radiation Oncology, Ludwig Maximilians Universität (LMU) Munich, LMU Hospital, Munich, Germany; 4Statistical Consulting for Science and Research, Berlin, Germany  \nCorrection to: Ann Surg Oncol (2025) 32:9116–9126  \n[https://doi.org/10.1245/s10434-025-18141-8](https://doi.org/10.1245/s10434-025-18141-8)  \nIn the published article, Tables 3 and 4 inadvertently omitted the modeled estimates of the Comprehensive Complication Index (CCI) by treatment group, which were included in the zero-inflated beta models as fixed effects. Table 3 has now been corrected to report the modeled probabilities of postoperative complications (CCI > 0) by  \ntreatment group, and Table 4 includes the expected CCI values (0 \u003C CCI \u003C 100) by treatment group. These corrections complete the presentation of the primary outcome but do not alter the study’s results or conclusions. The corrected Tables 3 and 4 are provided below.  \nCorresponding changes have been made to Supplemental Tables 3 and 4, which report the zero-inflated beta models for primary tumor patients, as well as to Tables 7 and 8, which report the models for recurrent tumor patients.  \nThe original article can be found online at [https://doi.org/10](https://doi.org/10) . 1245/s10434-025-18141-8.  \n© The Author(s) 2025  \nPublished online: 20 November 2025  \nM. Albertsmeier, MD  \n[e-mail: Markus.Albertsmeier@med.uni-muenchen.de](e-mail: Markus.Albertsmeier@med.uni-muenchen.de)  \nTABLE 3 Influence of neoadjuvant therapy, gender, transfusion, age, number of resected organs and recurrence on CCI in the model examining the probability of experiencing any postoperative complication (CCI > 0)  \n\n| Risk CCI > 0 (Mean, 95% CI) |  |\n| --- | --- |\n| Neoadjuvant therapy No therapy (n = 155)\u003Cbr>Chemotherapy (n = 10)\u003Cbr>Radiotherapy (n = 17)\u003Cbr>Chemotherapy + Radiotherapy (n = 7)\u003Cbr>Chemotherapy + RHT (n = 36)\u003Cbr>Chemotherapy + RHT + radiotherapy (n = 36)\u003Cbr>p value Gender\u003Cbr>Female (n = 114)\u003Cbr>Male (n = 147)\u003Cbr>p value\u003Cbr>Transfusion No (n = 132)\u003Cbr>Yes (n = 53)\u003Cbr>p value Age (y)\u003C 70\u003Cbr>≥ 70\u003Cbr>p value\u003Cbr>Number of resected organs \u003C 3\u003Cbr>≥ 3\u003Cbr>p value Recurrence\u003Cbr>No Yes\u003Cbr>p value | 0.68 (0 .57, 076) 0.80 (0.54, 0.95) 0.80 (0.61, 0.93) 0.50 (0.21, 0.79) 0.79 (0 .65, 0 . 89)\u003Cbr>0.78 (0 .64, 0 . 89)\u003Cbr>> 0.05 for all pairwise comparisons\u003Cbr>0.73 (0 .62, 0 . 82) 0,72 (0.6, 0.81) 0.77\u003Cbr>0.69 (0 .58, 0 .79) 0.83 (0 .71, 0 .91)\u003Cbr>0.03\u003Cbr>0.73 (0 .63, 0 . 81) 0.70 (0.58, 0.80) 0.49\u003Cbr>0.57 (0 .44, 0 .69) 0.79 (0 .62, 0 . 88)\u003Cbr>0.004\u003Cbr>0.72 (0.62, 0.80) 0.74 (0.59, 0.86) 0.65 |\n\nRHT, regional hyperthermia  \nTABLE 4 Influence of neoadjuvant therapy, gender, transfusion, age, number of resected organs and recurrence on CCI in the model examining the probability of experiencing  \nthe severity of postoperative complication (0 \u003C CCI \u003C 100)  \n\n| Expected CCI (Mean, 95% CI) |  |\n| --- | --- |\n| Neoadjuvant therapy No therapy (n = 155)\u003Cbr>Chemotherapy (n = 10)\u003Cbr>Radiotherapy (n = 17)\u003Cbr>Chemotherapy + Radiotherapy (n = 7)\u003Cbr>Chemotherapy + RHT (n = 36)\u003Cbr>Chemotherapy + RHT + radiotherapy (n = 36)\u003Cbr>p value Gender\u003Cbr>Female (n = 114)\u003Cbr>Male (n = 147)\u003Cbr>p value\u003Cbr>Transfusion No (n = 132)\u003Cbr>Yes (n = 53)\u003Cbr>p value Age (y)\u003C 70\u003Cbr>≥ 70\u003Cbr>p value\u003Cb","cbCaibIhXrz9MDCK","https://ap.wps.com/l/cbCaibIhXrz9MDCK","pdf",287693,"English","# Correction\n## Changes to Tables 3 and 4\n## Impact on supplemental and recurrent-tumor tables\n## Licensing and publication notes","[{\"question\":\"What was corrected in the published article?\",\"answer\":\"Tables 3 and 4 were initially missing the modeled Comprehensive Complication Index (CCI) estimates by treatment group.\"},{\"question\":\"What do the corrected Table 3 and Table 4 report?\",\"answer\":\"Table 3 reports modeled probabilities of postoperative complications (CCI \\u003e 0), while Table 4 includes expected CCI severity values (0 \\u003c CCI \\u003c 100) by treatment group.\"},{\"question\":\"Do the corrections change the study’s conclusions?\",\"answer\":\"No. The correction notice states that the corrected tables complete the primary outcome presentation and do not alter the study’s results or conclusions.\"}]","Correction - Correction - Surgery for Retroperitoneal Soft Tissue Sarcoma is Safe Following Multimodal Treatment with Regional Hyperthermia | PDF",1790686065]